About Finarix
Company Overview
Finarix is a trading brand operated by Global Prime Management EOOD, a company registered in Bulgaria. The firm was incorporated on 4 April 2019 and presents itself as an online brokerage, though its exact line of financial services remains ambiguous. Public records show the company has zero reported employees, which raises immediate questions about its operational capacity.
The broker’s website, finarix.com, appears to target an international clientele, but it provides notably little concrete information about its offerings. Unlike most legitimate brokers, Finarix does not disclose key information such as spreads, commissions, or available leverage on its account pages. This opacity is a significant red flag for any potential trader.
Regulatory Status
Finarix holds no recognized regulatory licence from any financial authority. Our cross‑checks with public registries in Bulgaria, the European Union, and other jurisdictions confirmed that Global Prime Management EOOD is not authorised to provide investment services. The broker does not claim regulation by any credible watchdog, and there is no evidence of client fund protection or segregation.
For retail traders, this means there is no legal recourse if something goes wrong. No compensation scheme would cover losses, and disputes would be extremely difficult to resolve. The absence of regulation is the single most critical warning sign when considering any broker.
Account Types
Finarix advertises three account tiers, each requiring a substantial minimum deposit. The Takeoff account demands a deposit between $250 and $2,499; the Standard account requires $2,500 to $9,999; and the Premium account starts at an unusually high $10,000, going up to $49,999.
What is missing from these tiers is any detail about what the trader actually receives. Typical brokerages differentiate accounts by spreads, commissions, leverage, and trading tools. Finarix provides none of this information, making it impossible to compare value across tiers. The high financial barriers suggest the broker is either targeting wealthy individuals or simply trying to extract as much money as possible upfront.
Funding and Withdrawals
The broker does not publicly list any deposit or withdrawal methods. There is no information about accepted currencies, processing times, or fees. In the real‑user record, multiple traders report depositing funds and then being unable to withdraw them, even after a year of waiting.
This complete lack of transparency around money movement is deeply concerning. Legitimate brokers clearly outline their banking policies, including payment providers and timeframes. Finarix’s unwillingness to share such basic operational details leaves clients entirely in the dark about how their money is handled.
Trading Instruments and Platforms
Finarix does not publish a list of tradable instruments. Whether it offers forex, CFDs, commodities, or cryptocurrencies is unknown. Similarly, the trading platform remains unspecified — there is no mention of MetaTrader, cTrader, or any proprietary solution.
This informational void is extremely unusual. Traders need to know not only what markets they can access but also the stability and features of the trading interface. Without this data, any decision to open an account becomes a blind gamble.
Who Is This Broker For?
Given the high minimum deposit requirements, Finarix would, on the surface, appear to cater to experienced or high‑net‑worth individuals. However, the total absence of regulatory protection, transparent pricing, or even a basic description of its trading environment makes it unsuitable for any retail trader.
The combination of untraceable ownership structures, zero regulatory oversight, and a track record of user‑reported withdrawal problems places this broker firmly outside the acceptable risk parameters of any conscientious investor. Even professional and institutional traders would find the lack of operational transparency unacceptable.
Overview compiled by FXCanary from regulatory records and public data. full Finarix review